Literature DB >> 9033200

Nerve function impairment in leprosy at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh.

J H Richardus1, K M Finlay, R P Croft, W C Smith.   

Abstract

This retrospective cohort study includes all new leprosy patients registered for multidrug therapy (MDT) in 1990 at the Danish-Bangladesh Leprosy Mission project in Bangladesh. The main objective was to determine the extent of nerve-function impairment (NFI) at diagnosis and at completion of MDT, and to identify opportunities for intervention and their relative impact on the prevention of disabilities (POD). A total of 786 patients were included; 486 males and 300 females. There were 315 PB, and 471 MB patients. In terms of the WHO leprosy disability grading system, at the time of diagnosis 31/315 (9.8%) had grade 1 or grade 2 disability in the PB group, and 177/471 (37.6%) in the MB group. The incidence rate of NFI during MDT was 3.5 per 100 person years at risk (PYR) in the PB group, and 7.5 per 100 PYR in the MB group. In the MB group 37 (7.9%) previously normal patients sustained NFI during MDT, whilst 19 (4.0%) with NFI at diagnosis showed complete recovery at completion of MDT. The most commonly involved nerves were the ulnar (motor function) and the posterior tibial nerves (sensibility). Reversal reactions were observed in 0.6% of the PB patients during MDT, giving an incidence rate of 1 per 100 PYR. The percentage of MB patients diagnosed with reversal during MDT was 14.2%, giving an incidence rate of 6 per 100 PYR. The percentage of MB patients diagnosed with ENL during MDT was 2.1%, with an incidence rate of 1 per 100 PYR. It was concluded that early detection of new cases of leprosy would prevent disabilities in more than 30% of all patients, thus having the highest impact in the quest for the prevention of disabilities. POD activities during and after MDT will prevent disabilities in approximately 10% of all cases. This study also indicates that treatment with prednisolone is effective and should be available at field level for all patients with recent NFI.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9033200     DOI: 10.5935/0305-7518.19960030

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  7 in total

Review 1.  Neurology and the skin.

Authors:  O Hurko; T T Provost
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

2.  Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study.

Authors:  W Cairns S Smith; Peter G Nicholls; Loretta Das; Pramila Barkataki; Sujai Suneetha; Lavanya Suneetha; Rupendra Jadhav; P S S Sundar Rao; Einar P Wilder-Smith; Diana N J Lockwood; Wim H van Brakel
Journal:  PLoS Negl Trop Dis       Date:  2009-08-11

3.  Progression of leprosy neuropathy: a case series study.

Authors:  Robson T Vital; Ximena Illarramendi; Osvaldo Nascimento; Mariana A Hacker; Euzenir N Sarno; Marcia R Jardim
Journal:  Brain Behav       Date:  2012-05       Impact factor: 2.708

4.  Towards the elimination of leprosy in Yunnan, China: A time-series analysis of surveillance data.

Authors:  Tie-Jun Shui; Heng Long; Li Xiong; Xiao-Hong Zhang; Jun He; Xiaohua Chen
Journal:  PLoS Negl Trop Dis       Date:  2021-03-16

Review 5.  A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.

Authors:  Carlijn G N Voorend; Erik B Post
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

6.  Leprosy New Case Detection Trends and the Future Effect of Preventive Interventions in Pará State, Brazil: A Modelling Study.

Authors:  Haroldo José de Matos; David J Blok; Sake J de Vlas; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2016-03-03

7.  Disabilities in leprosy: an open, retrospective analyses of institutional records.

Authors:  Santoshdev P Rathod; Ashish Jagati; Pooja Chowdhary
Journal:  An Bras Dermatol       Date:  2019-12-28       Impact factor: 1.896

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.